4D Molecular Therapeutics (NASDAQ:FDMT) Coverage Initiated by Analysts at Barclays

Barclays assumed coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note released on Wednesday, MarketBeat reports. The brokerage issued an overweight rating and a $33.00 target price on the stock.

A number of other analysts have also recently commented on the company. Chardan Capital reiterated a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 7th. Finally, Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.25.

4D Molecular Therapeutics Trading Up 1.3%

Shares of NASDAQ:FDMT opened at $8.60 on Wednesday. The firm has a 50 day simple moving average of $9.04 and a 200-day simple moving average of $8.24. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34. The company has a market capitalization of $491.32 million, a PE ratio of -2.29 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, equities research analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors have recently modified their holdings of FDMT. AQR Capital Management LLC acquired a new position in 4D Molecular Therapeutics during the first quarter worth $46,000. Millennium Management LLC boosted its position in shares of 4D Molecular Therapeutics by 15.0% during the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after purchasing an additional 213,264 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth $39,000. Privium Fund Management B.V. lifted its stake in shares of 4D Molecular Therapeutics by 50.7% in the second quarter. Privium Fund Management B.V. now owns 197,458 shares of the company’s stock valued at $733,000 after purchasing an additional 66,458 shares during the period. Finally, Peapod Lane Capital LLC boosted its holdings in 4D Molecular Therapeutics by 62.6% during the second quarter. Peapod Lane Capital LLC now owns 318,537 shares of the company’s stock worth $1,182,000 after buying an additional 122,684 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.